A narrative review of applications and enhancements of ChatGPT in respiratory medicine

Clinical eHealth Pub Date : 2024-12-01 DOI:10.1016/j.ceh.2024.12.006

Jun Qi Lin , Zi Xuan Hua , Liu Zhang , Ying Ni Lin , Yong Jie Ding , Xi Xi Chen , Shi Qi Li , Yi Wang , Qing Yun Li

{"title":"A narrative review of applications and enhancements of ChatGPT in respiratory medicine","authors":"Jun Qi Lin , Zi Xuan Hua , Liu Zhang , Ying Ni Lin , Yong Jie Ding , Xi Xi Chen , Shi Qi Li , Yi Wang , Qing Yun Li","doi":"10.1016/j.ceh.2024.12.006","DOIUrl":null,"url":null,"abstract":"<div><div>ChatGPT, a chatbot program pioneered by OpenAI and launched on 2022, stands alongside other notable large language models (LLMs) such as Google’s Bard Model and Baidu’s ERNIE Bot Model. These AI-powered tools have become integral to daily life, exerting considerable influence. Recently, AI’s medical applications gain traction as momentum grows. Meanwhile. chronic respiratory diseases pose a substantial global health burden, affecting nearly 550 million people in 2017, an increase of 39.8% compared to 1990. They remain a leading cause of death and disability worldwide, second only to cardiovascular diseases and cancer. The respiratory field grapples with unmet needs like antibiotic and anti-tuberculosis drug resistance, respiratory epidemics, and high prevalence of lung tumors, etc. Although the utilization of ChatGPT in medicine has been actively explored, its application in respiratory medicine remains in the early stages. In this context, we outline ChatGPT’s current respiratory medicine applications, address potential limitations, and envision future avenues for its advancement and development.</div></div>","PeriodicalId":100268,"journal":{"name":"Clinical eHealth","volume":"7 ","pages":"Pages 200-206"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical eHealth","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2588914124000194","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

ChatGPT, a chatbot program pioneered by OpenAI and launched on 2022, stands alongside other notable large language models (LLMs) such as Google’s Bard Model and Baidu’s ERNIE Bot Model. These AI-powered tools have become integral to daily life, exerting considerable influence. Recently, AI’s medical applications gain traction as momentum grows. Meanwhile. chronic respiratory diseases pose a substantial global health burden, affecting nearly 550 million people in 2017, an increase of 39.8% compared to 1990. They remain a leading cause of death and disability worldwide, second only to cardiovascular diseases and cancer. The respiratory field grapples with unmet needs like antibiotic and anti-tuberculosis drug resistance, respiratory epidemics, and high prevalence of lung tumors, etc. Although the utilization of ChatGPT in medicine has been actively explored, its application in respiratory medicine remains in the early stages. In this context, we outline ChatGPT’s current respiratory medicine applications, address potential limitations, and envision future avenues for its advancement and development.

查看原文本刊更多论文

综述了ChatGPT在呼吸医学中的应用和增强

ChatGPT是由OpenAI开发的聊天机器人程序，于2022年推出，与b谷歌的Bard模型和b百度的ERNIE Bot模型等其他著名的大型语言模型（llm）并列。这些人工智能工具已经成为日常生活中不可或缺的一部分，产生了相当大的影响。最近，随着势头的增长，人工智能的医疗应用获得了牵引力。与此同时。慢性呼吸系统疾病造成了巨大的全球健康负担，2017年影响了近5.5亿人，比1990年增加了39.8%。它们仍然是全世界死亡和残疾的主要原因，仅次于心血管疾病和癌症。呼吸领域面临着未满足的需求，如抗生素和抗结核药物耐药性、呼吸道流行病和高患病率的肺部肿瘤等。虽然ChatGPT在医学上的应用已被积极探索，但其在呼吸医学上的应用仍处于早期阶段。在此背景下，我们概述了ChatGPT目前的呼吸医学应用，解决了潜在的局限性，并展望了其进步和发展的未来途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical eHealth

CiteScore

8.10

自引率

0.00%

发文量